Applications of satellite snow cover in computerized short-term streamflow forecasting

A procedure is described whereby the correlation between: (1) satellite derived snow-cover depletion and (2) residual snowpack water equivalent, can be used to update computerized residual flow forecasts for the Conejos River in southern Colorado

LANDSAT derived snowcover as an input variable for snowmelt runoff forecasting in south central Colorado

There are no author-identified significant results in this report

Snowpack ground truth: Radar test site, Steamboat Springs, Colorado, 8-16 April 1976

Ground-truth data taken at Steamboat Springs, Colorado is presented. Data taken during the period April 8, 1976 - April 16, 1976 included the following: (1) snow depths and densities at selected locations (using a Mount Rose snow tube); (2) snow pits for temperature, density, and liquid water determinations using the freezing calorimetry technique and vertical layer classification; (3) snow walls were also constructed of various cross sections and documented with respect to sizes and snow characteristics; (4) soil moisture at selected locations; and (5) appropriate air temperature and weather data

Applications systems verification and transfer project. Volume 4: Operational applications of satellite snow cover observations. Colorado Field Test Center

The study was conducted on six watersheds ranging in size from 277 km to 3460 km in the Rio Grande and Arkansas River basins of southwestern Colorado. Six years of satellite data in the period 1973-78 were analyzed and snowcover maps prepared for all available image dates. Seven snowmapping techniques were explored; the photointerpretative method was selected as the most accurate. Three schemes to forecast snowmelt runoff employing satellite snowcover observations were investigated. They included a conceptual hydrologic model, a statistical model, and a graphical method. A reduction of 10% in the current average forecast error is estimated when snowcover data in snowmelt runoff forecasting is shown to be extremely promising. Inability to obtain repetitive coverage due to the 18 day cycle of LANDSAT, the occurrence of cloud cover and slow image delivery are obstacles to the immediate implementation of satellite derived snowcover in operational streamflow forecasting programs

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

Background. Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of renal anaemia may be possible at extended dosing intervals; however, few studies were randomized, results varied, and comparisons between agents were absent. We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epoetin beta and darbepoetin alfa administered once monthly

Product rule for gauge invariant Weyl symbols and its application to the semiclassical description of guiding center motion

We derive a product rule for gauge invariant Weyl symbols which provides a generalization of the well-known Moyal formula to the case of non-vanishing electromagnetic fields. Applying our result to the guiding center problem we expand the guiding center Hamiltonian into an asymptotic power series with respect to both Planck's constant $\hbar$ and an adiabaticity parameter already present in the classical theory. This expansion is used to determine the influence of quantum mechanical effects on guiding center motion.Comment: 24 pages, RevTeX, no figures; shortened version will be published in J.Phys.

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures

Despite important progress in understanding the molecular factors underlying the development of cancer and the improvement in response rates with new drugs, long-term survival is still disappointing for most common solid tumours. This might be because very little of the modest gain for patients is the result of the new compounds discovered and marketed recently. An assessment of the regulatory agencies' performance may suggest improvements. The present analysis summarizes and evaluates the type of studies and end points used by the EMEA to approve new anticancer drugs, and discusses the application of current regulations. This report is based on the information available on the EMEA web site. We identified current regulatory requirements for anticancer drugs promulgated by the agency and retrieved them in the relevant directory; information about empirical evidence supporting the approval of drugs for solid cancers through the centralised procedure were retrieved from the European Public Assessment Report (EPAR). We surveyed documents for drug applications and later extensions from January 1995, when EMEA was set up, to December 2004. We identified 14 anticancer drugs for 27 different indications (14 new applications and 13 extensions). Overall, 48 clinical studies were used as the basis for approval; randomised comparative (clinical) trial (RCT) and Response Rate were the study design and end points most frequently adopted (respectively, 25 out of 48 and 30 out of 48). In 13 cases, the EPAR explicitly reported differences between arms in terms of survival: the range was 0–3.7 months, and the mean and median differences were 1.5 and 1.2 months. The majority of studies (13 out of 27, 48%) involved the evaluation of complete and/or partial tumour responses, with regard to the end points supporting the 27 indications. Despite the recommendations of the current EMEA guidance documents, new anticancer agents are still often approved on the basis of small single arm trials that do not allow any assessment of an ‘acceptable and extensively documented toxicity profile' and of end points such as response rate, time to progression or progression-free survival which at best can be considered indicators of anticancer activity and are not ‘justified surrogate markers for clinical benefit'. Anticipating an earlier than ideal point along the drug approval path and the use of not fully validated surrogate end points in nonrandomised trials looks like a dangerous shortcut that might jeopardise consumers' health, leading to unsafe and ineffective drugs being marketed and prescribed. The present Note for Guidance for new anticancer agents needs revising. Drugs must be rapidly released for patients who need them but not be at the expense of adequate knowledge about the real benefit of the drugs

Societal Burden of Clinically Anxious Youth Referred for Treatment: A Cost-of-illness Study

A prevalence-based cost-of-illness study using a societal perspective was conducted to investigate the cost-of-illness in clinically anxious youth aged 8–18 in The Netherlands. Discriminant validity of the cost diary used was obtained by comparing costs of families with an anxious child (n = 118) to costs of families from the general population (n = 41). To examine the convergent validity, bottom-up acquired costs derived from cost diaries were compared to top-down acquired costs obtained from national registrations. Bottom-up acquired costs measured by means of cost diaries amounted to €2,748 per family of a clinically referred anxious child per annum. Societal costs of families with clinically anxious children were almost 21 times as high compared to families from the general population. With respect to convergent validity, total health care costs using the bottom-up approach from clinically anxious children were quite comparable to those of top-down data of anxious children, although costs within the subcategories differed considerably. Clinical anxiety disorders in childhood cost the Dutch society more than 20 million euros a year. Based on results of discriminate and convergent validity, the cost diary seems a valid method in establishing cost-of-illness in childhood anxiety disorders

Low and moderate, rather than high intensity strength exercise induces benefit regarding plasma lipid profile

<p>Abstract</p> <p>Background</p> <p>The effects of chronic aerobic exercise upon lipid profile has been previously demonstrated, but few studies showed this effect under resistance exercise conditions.</p> <p>Objective</p> <p>The aim of this study was to examine the effects of different resistance exercise loads on blood lipids.</p> <p>Methods</p> <p>Thirty healthy, untrained male volunteers were allocated randomly into four groups based at different percentages of one repetition maximum (1 RM); 50%-1 RM, 75%-1 RM, 90%-1 RM, and 110%-1 RM. The total volume (sets × reps × load) of the exercise was equalized. The lipid profile (Triglycerides [TG], HDL-cholesterol [HDL-c], LDL-cholesterol, and Total cholesterol) was determined at rest and after 1, 24, 48 and 72 h of resistance exercise.</p> <p>Results</p> <p>The 75%-1 RM group demonstrated greater TG reduction when compared to other groups (p < 0.05). Additionally, the 110%-1 RM group presented an increased TG concentration when compared to 50% and 75% groups (p = 0.01, p = 0.01, respectively). HDL-c concentration was significantly greater after resistance exercise in 50%-1 RM and 75%-1 RM when compared to 110%-1 RM group (p = 0.004 and p = 0.03, respectively). Accordingly, the 50%-1 RM group had greater HDL-c concentration than 110%-1 RM group after 48 h (p = 0.05) and 72 h (p = 0.004), respectively. Finally, The 50% group has showed lesser LDL-c concentration than 110% group after 24 h (p = 0.007). No significant difference was found in Total Cholesterol concentrations.</p> <p>Conclusion</p> <p>These results indicate that the acute resistance exercise may induce changes in lipid profile in a specific-intensity manner. Overall, low and moderate exercise intensities appear to be promoting more benefits on lipid profile than high intensity. Long term studies should confirm these findings.</p